World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
29241
World Ranking
10162
National Ranking
561

Ulrich Keilholz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ulrich Keilholz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 642 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ulrich Keilholz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ulrich Keilholz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ulrich Keilholz is affiliated with Charité - University Medicine Berlin in Germany. Their research primarily spans the field of medicine, with a focus on oncology and related subfields. The main areas of study include oncology, cancer research, pulmonary and respiratory medicine, molecular biology, and pathology and forensic medicine.

Keilholz's work covers diverse topics within cancer science. Key research themes include:

  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Cells and Metastasis
  • Head and Neck Cancer Studies
  • Genetic factors in colorectal cancer
  • Colorectal Cancer Treatments and Studies

They have contributed to the scientific community through numerous publications, frequently appearing in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, bioRxiv (Cold Spring Harbor Laboratory), and Cancer Research.

Some of the recent papers that include Ulrich Keilholz as an author are:

  • ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee, 2020, Annals of Oncology

Among notable publications co-authored alongside scientists such as Damian Rieke, Frederick Klauschen, Konrad Klinghammer, Stefan Fröhling, and Ulrich Keller, Keilholz's research contributions stand within high-impact clinical and translational oncology topics.

Frequent co-authors include:

  • Damian Rieke
  • Frederick Klauschen
  • Konrad Klinghammer
  • Stefan Fröhling
  • Ulrich Keller

Frequent publication venues with contributions from Keilholz include:

  • Annals of Oncology
  • European Journal of Cancer
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Research

Best Publications

  • Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

    Ezra E W Cohen;Denis Soulières;Christophe Le Tourneau;Christophe Le Tourneau;Christophe Le Tourneau;José Dinis

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

    Alexander M. M. Eggermont;Stefan Suciu;Mario Santinami;Alessandro Testori

  • Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

    Claus Garbe;Thomas K. Eigentler;Ulrich Keilholz;Axel Hauschild

  • Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    R. Dummer;A. Hauschild;N. Lindenblatt;G. Pentheroudakis

  • Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    Jean Pascal H Machiels;Robert I. Haddad;Jérôme Fayette;Lisa F. Licitra

  • Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

    Alexander M. M. Eggermont;Stefan Suciu;Rona Mackie;Wlodzimierz Ruka

  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

    Ulrich Keilholz;Jeffrey Weber;James H. Finke;Dmitry I. Gabrilovich

  • A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

    Ulrich Keilholz;Anne Letsch;Antonia Busse;Anne Marie Asemissen

  • CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia.

    Carmen Scheibenbogen;Anne Letsch;Eckhard Thiel;Alexander Schmittel

  • A clinical development paradigm for cancer vaccines and related biologics.

    Axel Hoos;Giorgio Parmiani;Kristen Hege;Mario Sznol

  • Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Stefan Suciu;Alessandro Testori;Mario Santinami

  • Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors

    Moritz Schütte;Thomas Risch;Nilofar Abdavi-Azar;Karsten Boehnke

  • Circulating tumor cells: the 'leukemic phase' of solid cancers.

    Simone Mocellin;Ulrich Keilholz;Carlo Riccardo Rossi;Donato Nitti

  • Natural T cell immunity against cancer.

    Dirk Nagorsen;Carmen Scheibenbogen;Francesco M. Marincola;Anne Letsch

  • Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

    Ulrich Keilholz;Christian Conradt;Sewa S Legha;David Khayat

  • Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

    Wim H J Kruit;Stefan Suciu;Brigitte Dreno;Laurent Mortier

  • Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas

    R. Max;R.R.C.M. Gerritsen;P.T.G.A. Nooijen;S.L. Goodman

  • Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial

    Henrik Schmidt;Stefan Suciu;Cornelis J.A. Punt;Martin Gore

  • Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

    Dan P. Zandberg;Alain P. Algazi;Antonio Jimeno;James S. Good

Frequent Co-Authors

Eckhard Thiel
Eckhard Thiel Charité - University Medicine Berlin
Carmen Scheibenbogen
Carmen Scheibenbogen Charité - University Medicine Berlin
Alexander M.M. Eggermont
Alexander M.M. Eggermont Institut Gustave Roussy
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Stefan Suciu
Stefan Suciu European Organisation for Research and Treatment of Cancer
Reinhard Dummer
Reinhard Dummer University of Zurich
Axel Hauschild
Axel Hauschild Kiel University
Reinhold Schäfer
Reinhold Schäfer Charité - University Medicine Berlin
Claus Garbe
Claus Garbe University of Tübingen
Lisa Licitra
Lisa Licitra University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always require a traditional medical school route. Prospective students have a variety of related online degrees and career pathways to choose from, which offer flexibility and different entry points into the healthcare industry.

For those interested in the administrative and business side of healthcare, a healthcare administration online degree can provide vital management skills and open doors to a wide range of roles in hospitals, clinics, and insurance companies.

Individuals looking to start working quickly may consider medical billing and coding schools with financial aid, which prepare students for in-demand jobs that ensure the accuracy and privacy of healthcare records.

If your passion is direct patient care, there are nursing school that does not require teas test options, allowing you to bypass some typical admissions exams. For current nurses looking to advance, asn to nurse practitioner programs offer bridge programs to higher clinical roles.

These alternative pathways provide flexible, accessible options for entering or advancing in the healthcare field—no matter your background or previous experience.

Best Scientists Citing Ulrich Keilholz

Trending Scientists

Recently Published Articles